ORIC - ORIC Pharmaceuticals: Rally Seems Overdone
2024-03-29 05:29:56 ET
Summary
- ORIC Pharmaceuticals' stock has seen significant gains since releasing promising data from its ORIC-114 program, which induced multiple partial responses in NSCLC patients.
- The company focuses on developing therapies to counter resistance mechanisms in cancer, with three programs in the clinic.
- ORIC has a strong balance sheet with approximately $350 million in cash and marketable securities, providing funding into 2H26.
- A full investment analysis around ORIC Pharmaceuticals follows in the paragraphs below.
Shares of cancer resistance concern ORIC Pharmaceuticals, Inc. (ORIC) have seen huge gains since late October 2023, after it released promising initial data from its ORIC-114 program. The brain-penetrant candidate induced multiple partial responses in NSCLC patients, including a complete response in one who had treatment-naïve brain metastases in a Phase 1b study. With a recent private placement providing funding into 2H26 and two other early-stage programs in the clinic, this clinical stage biotech firm merited a deeper dive. An analysis follows below....
ORIC Pharmaceuticals: Rally Seems Overdone